Kingswood Wealth Advisors LLC Has $294,000 Holdings in Zoetis Inc. (NYSE:ZTS)

Kingswood Wealth Advisors LLC decreased its position in Zoetis Inc. (NYSE:ZTS) by 28.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,807 shares of the company’s stock after selling 728 shares during the period. Kingswood Wealth Advisors LLC’s holdings in Zoetis were worth $294,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC purchased a new position in shares of Zoetis during the third quarter valued at $31,000. First Personal Financial Services acquired a new position in shares of Zoetis in the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP purchased a new stake in shares of Zoetis in the third quarter worth approximately $33,000. Dunhill Financial LLC boosted its holdings in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares during the period. Finally, Quarry LP grew its position in Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Trading Down 1.1 %

Shares of NYSE:ZTS opened at $170.81 on Friday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock’s 50-day moving average is $169.74 and its 200-day moving average is $179.54. The company has a market cap of $77.06 billion, a P/E ratio of 32.11, a P/E/G ratio of 2.70 and a beta of 0.89. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the previous year, the business posted $1.36 EPS. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. Equities research analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. This is an increase from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. Zoetis’s payout ratio is presently 37.59%.

Analyst Ratings Changes

A number of research firms have issued reports on ZTS. Stifel Nicolaus cut their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. UBS Group assumed coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. JPMorgan Chase & Co. boosted their price target on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $215.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.